EUVIMEDEUVIMED entdecken
Crossref

Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin

Victor Kung, Megan Delisle, Sue Alves, Faheez Mohamed, Tom Cecil, Brendan Moran

European Journal of Surgical Oncology · 2023

DOI: 10.1016/j.ejso.2023.107045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2023. Verfasst von Victor Kung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, RG24 9NA, United Kingdom. Electronic addres…. Hauptthemen laut MEDLINE: Pseudomyxoma Peritonei, Appendiceal Neoplasms, Hyperthermia, Induced. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Optimal management of pseudomyxoma peritonei (PMP) is by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), which can achieve 20-year disease-free, and overall survival. There is limited information on the health-related quality of life (HRQOL) of PMP survivors beyond five years. We report longitudinal HRQOL in patients with PMP of appendiceal origin up to 17-years after their CRS and HIPEC in 2003-2004. METHODS: Patients had HRQOL assessed with EORTC QLQ-C30 questionnaires pre-operatively, and at 1-, 10- and 17-years post-operatively. Comparisons in global health-related QOL (global-HRQOL) measures were made with (1) an age- and sex-matched normal European population, (2) between patients who underwent complete cytoreduction (CRS CC0/1) versus maximal tumor debulking (MTD), and (3) between those with and without peritoneal recurrence. RESULTS: Forty-six patients underwent CRS & HIPEC for appendiceal PMP. One patient withdrew from the study. Of the 45 patients, 23 patients were alive at ten and 15 patients at 17-years post-operatively. 21/23 (91%) and 14/15 patients (93%) completed questionnaires respectively. Pre-operatively, patients had significantly lower global-HRQOL compared with the reference population. Over follow-up, patients experienced improvements in their global-HRQOL. By post-operative year-10 and -17, there was no difference between the global-HRQOL of patients and reference population. As expected, patients with CC0/1 and without peritoneal tumor recurrence had better global-HRQOL at ten- and 17-years post-operatively compared with those with MTD or recurrence. CONCLUSIONS: Optimal CRS and HIPEC is an effective treatment for appendiceal PMP that can achieve long-term survival. HRQOL is excellent and maintained, in those who have CC0/1 without recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomyxoma PeritoneiAppendiceal NeoplasmsHyperthermia, InducedHumansCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyQuality of LifeNeoplasm Recurrence, LocalCombined Modality TherapyRetrospective Studies

Stichwörter der Autor:innen

Cytoreductive surgeryHealth-related quality of lifeHyperthermic intraperitoneal chemotherapyPseudomyxoma peritonei

Autor:innen und Institutionen

  • Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, RG24 9NA, United Kingdom. Electronic address: victor.kung@hhft.nhs.uk.
  • Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, RG24 9NA, United Kingdom; Department of Surgery, University of Ottawa, The Ottawa Hospital, General Campus, 501 S…
  • Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, RG24 9NA, United Kingdom. Electronic address: sue.alves@hhft.nhs.uk.
  • Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, RG24 9NA, United Kingdom. Electronic address: faheez.mohamed@hhft.nhs.uk.
  • Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, RG24 9NA, United Kingdom. Electronic address: tom.cecil@hhft.nhs.uk.
  • Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, RG24 9NA, United Kingdom. Electronic address: Brendan.Moran@hhft.nhs.uk.

Zitieren

APA

Kung, V., Delisle, M., Alves, S., Mohamed, F., Cecil, T., & Moran, B. (2023). Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2023.107045

Vancouver

Kung V, Delisle M, Alves S, Mohamed F, Cecil T, Moran B. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin. European Journal of Surgical Oncology. 2023. doi:10.1016/j.ejso.2023.107045

BibTeX
@article{Kung2023,
  author = {Kung, Victor and Delisle, Megan and Alves, Sue and Mohamed, Faheez and Cecil, Tom and Moran, Brendan},
  title = {Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin},
  journal = {European Journal of Surgical Oncology},
  year = {2023},
  doi = {10.1016/j.ejso.2023.107045}
}
Kostenlos starten →